Aspen Pharmacare Holdings Ltd
F:LDZU
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Aspen Pharmacare Holdings Ltd
F:LDZU
|
ZA |
Aspen Pharmacare Holdings Ltd
Aspen Pharmacare ist ein Pharmaunternehmen, das Arzneimittel herstellt und vertreibt, hauptsächlich marken- und generische verschreibungspflichtige Arzneimittel, Injektionspräparate und andere auf Krankenhäuser ausgerichtete Produkte. Es verfügt zudem über Fertigungskapazitäten, die in einigen Fällen die Produktion für Dritte unterstützen. Das Unternehmen beliefert Apotheken, Krankenhäuser, staatliche Stellen, Großhändler und andere Gesundheitskäufer, die auf eine verlässliche Versorgung mit essentiellen Arzneimitteln angewiesen sind. Aspen erzielt Einnahmen durch den Verkauf eigener Arzneimittel und durch die Belieferung über sein Produktions- und Vertriebsnetz. Praktisch nimmt es eine Mittlerrolle in der Gesundheitswertschöpfungskette ein: Es verarbeitet Wirkstoffe, stellt fertige Arzneimittel her und bringt diese in medizinische und Einzelhandelskanäle. Das bedeutet, dass das Geschäft weniger von Verbraucherbranding abhängt und mehr davon, ein verlässlicher Lieferant von Produkten zu sein, die Gesundheitssysteme tagtäglich nutzen. Was Aspen unterscheidet, ist der Fokus auf breit zugängliche Arzneimittel und auf Märkte, in denen lokale Fertigung und Versorgungssicherheit eine große Rolle spielen. Es ist kein rein forschungsgetriebenes Arzneimittelentwicklungsunternehmen; vielmehr ist es näher an einem großskaligen Hersteller und Distributor essenzieller Pharmazeutika. Für Investoren bedeutet das ein auf Volumen, effiziente Lieferkettenumsetzung und langfristige Kundenbeziehungen im Gesundheitswesen ausgerichtetes Geschäftsmodell.
Aspen Pharmacare ist ein Pharmaunternehmen, das Arzneimittel herstellt und vertreibt, hauptsächlich marken- und generische verschreibungspflichtige Arzneimittel, Injektionspräparate und andere auf Krankenhäuser ausgerichtete Produkte. Es verfügt zudem über Fertigungskapazitäten, die in einigen Fällen die Produktion für Dritte unterstützen. Das Unternehmen beliefert Apotheken, Krankenhäuser, staatliche Stellen, Großhändler und andere Gesundheitskäufer, die auf eine verlässliche Versorgung mit essentiellen Arzneimitteln angewiesen sind.
Aspen erzielt Einnahmen durch den Verkauf eigener Arzneimittel und durch die Belieferung über sein Produktions- und Vertriebsnetz. Praktisch nimmt es eine Mittlerrolle in der Gesundheitswertschöpfungskette ein: Es verarbeitet Wirkstoffe, stellt fertige Arzneimittel her und bringt diese in medizinische und Einzelhandelskanäle. Das bedeutet, dass das Geschäft weniger von Verbraucherbranding abhängt und mehr davon, ein verlässlicher Lieferant von Produkten zu sein, die Gesundheitssysteme tagtäglich nutzen.
Was Aspen unterscheidet, ist der Fokus auf breit zugängliche Arzneimittel und auf Märkte, in denen lokale Fertigung und Versorgungssicherheit eine große Rolle spielen. Es ist kein rein forschungsgetriebenes Arzneimittelentwicklungsunternehmen; vielmehr ist es näher an einem großskaligen Hersteller und Distributor essenzieller Pharmazeutika. Für Investoren bedeutet das ein auf Volumen, effiziente Lieferkettenumsetzung und langfristige Kundenbeziehungen im Gesundheitswesen ausgerichtetes Geschäftsmodell.
Record H2 Performance: Aspen delivered record second-half sales of ZAR 21 billion and normalized EBITDA over ZAR 6 billion, marking the strongest H2 in its history.
Full-Year EBITDA Guidance Met: Normalized EBITDA reached ZAR 11.1 billion, slightly ahead of prior guidance, despite headwinds from COVID vaccine revenue loss and currency impacts.
Double-Digit Revenue Growth Expected: Management projects double-digit reported revenue growth for FY24, with results heavily weighted to the second half.
Manufacturing Upside: New sterile manufacturing contracts are expected to drive significant growth, with ZAR 2 billion to ZAR 4 billion in revenue contribution guided for FY25–26.
Foreign Exchange Headwind: Foreign exchange swings cut into headline earnings, with a ZAR 434 million loss versus a gain last year.
Dividend Increase: The annual dividend was raised by 5%, reflecting confidence in future cash flows.
Operational Focus: Execution on new contracts and manufacturing volumes is seen as the critical driver for future growth and margin improvement.
Geschäftsleitung
Stephen Bradley Saad is a prominent South African businessman, best known as the founder and Group Chief Executive of Aspen Pharmacare Holdings Limited, the largest pharmaceutical company in Africa. He was born in Durban, South Africa, and completed his education at the University of Natal (now the University of KwaZulu-Natal), where he earned his Bachelor of Commerce (BCom) degree. Saad is also a Chartered Accountant (CA), having qualified in South Africa. Stephen Saad's entrepreneurial journey began in earnest when he co-founded Aspen in 1997. Under his leadership, the company has grown significantly, expanding its operations internationally and acquiring several companies to diversify its product offerings. Aspen has become a key player in generic and specialty drugs, operating in over 150 countries. Stephen Saad's contributions to the pharmaceutical industry and his business acumen have earned him numerous accolades. He is known for his strategic vision and commitment to improving healthcare accessibility globally. His leadership has been instrumental in positioning Aspen as a major force in the global pharmaceutical landscape. Aside from his business achievements, Saad is involved in various philanthropic endeavors, focusing on healthcare and education. His leadership style and dedication to both business and social initiatives have made him a respected figure in the corporate world.
He was born in Durban, South Africa, and completed his education at the University of Natal (now the University of KwaZulu-Natal), where he earned his Bachelor of Commerce (BCom) degree. Saad is also a Chartered Accountant (CA), having qualified in South Africa.
Stephen Saad's entrepreneurial journey began in earnest when he co-founded Aspen in 1997. Under his leadership, the company has grown significantly, expanding its operations internationally and acquiring several companies to diversify its product offerings. Aspen has become a key player in generic and specialty drugs, operating in over 150 countries.
Stephen Saad's contributions to the pharmaceutical industry and his business acumen have earned him numerous accolades. He is known for his strategic vision and commitment to improving healthcare accessibility globally. His leadership has been instrumental in positioning Aspen as a major force in the global pharmaceutical landscape.
Aside from his business achievements, Saad is involved in various philanthropic endeavors, focusing on healthcare and education. His leadership style and dedication to both business and social initiatives have made him a respected figure in the corporate world.
Michael Guy Attridge is a prominent figure in the pharmaceutical industry, particularly known for his role at Aspen Pharmacare Holdings Ltd. He serves as the Deputy Group Chief Executive of the company, which is a leading global player in the production and distribution of pharmaceutical products. With a strong academic background, Attridge holds a Bachelor of Commerce degree and is a Chartered Accountant in South Africa (CA(SA)). His expertise in financial management and strategic planning has been instrumental in guiding Aspen Pharmacare's growth and expansion. Attridge has been with Aspen for several years, during which time he has held various leadership positions, contributing significantly to the company's success. His leadership style is characterized by a focus on operational excellence and innovation, ensuring that Aspen maintains its competitive edge in the rapidly evolving pharmaceutical landscape. Under his stewardship, Aspen has developed a strong portfolio of high-quality, affordable medicines, catering to a diverse range of therapeutic areas and reaching numerous countries worldwide. Attridge's commitment to the company's vision and values has reinforced its reputation as a trusted healthcare provider. Overall, Michael Guy Attridge's contributions have been vital in shaping Aspen Pharmacare into a prominent, globally recognized pharmaceutical corporation.
With a strong academic background, Attridge holds a Bachelor of Commerce degree and is a Chartered Accountant in South Africa (CA(SA)). His expertise in financial management and strategic planning has been instrumental in guiding Aspen Pharmacare's growth and expansion.
Attridge has been with Aspen for several years, during which time he has held various leadership positions, contributing significantly to the company's success. His leadership style is characterized by a focus on operational excellence and innovation, ensuring that Aspen maintains its competitive edge in the rapidly evolving pharmaceutical landscape.
Under his stewardship, Aspen has developed a strong portfolio of high-quality, affordable medicines, catering to a diverse range of therapeutic areas and reaching numerous countries worldwide. Attridge's commitment to the company's vision and values has reinforced its reputation as a trusted healthcare provider.
Overall, Michael Guy Attridge's contributions have been vital in shaping Aspen Pharmacare into a prominent, globally recognized pharmaceutical corporation.
Zizipho Mmango serves as the Executive Officer of Human Resources at Aspen Pharmacare Holdings Ltd, a prominent global pharmaceutical company. In her role, she is responsible for overseeing the company's human resource strategies and initiatives, which include talent management, development programs, and organizational effectiveness. Zizipho's leadership plays a crucial part in fostering a supportive and efficient workplace culture that aligns with Aspen's strategic goals. Her experience in HR management and dedication to employee engagement contribute significantly to the company's success in the highly competitive pharmaceutical industry.
Raeesa Khan is an experienced executive serving at Aspen Pharmacare Holdings Ltd, a global pharmaceutical company based in South Africa. In her role, she plays an integral part in the operations and strategic initiatives of the company. With a wealth of experience in the pharmaceutical industry, Khan has contributed to Aspen's growth and development through her expertise in various facets of the business, including corporate strategy, governance, and risk management. Khan has held various positions within the organization, where she has been instrumental in driving initiatives that focus on operational excellence and innovation. Her leadership and strategic insights support Aspen Pharmacare's mission to provide affordable and quality healthcare solutions across the globe. Her career reflects a commitment to enhancing the value and impact of the pharmaceutical industry, both locally and internationally.
Khan has held various positions within the organization, where she has been instrumental in driving initiatives that focus on operational excellence and innovation. Her leadership and strategic insights support Aspen Pharmacare's mission to provide affordable and quality healthcare solutions across the globe. Her career reflects a commitment to enhancing the value and impact of the pharmaceutical industry, both locally and internationally.
Trevor Julian Ziman has been a significant figure in the pharmaceutical industry, particularly with his role at Aspen Pharmacare Holdings Ltd, where he serves as the Regional Chief Executive Officer of Asia Pacific. Aspen Pharmacare, a globally recognized pharmaceutical company, benefits from his extensive experience and leadership skills in the industry. With his deep insights into the Asia Pacific market, Mr. Ziman has contributed to the company's strategic growth and operational excellence in the region. His role involves overseeing operations, driving commercial strategies, and ensuring compliance with regional regulations. His leadership is crucial as Aspen continues to expand its footprint and enhance its product offerings in the Asia Pacific region. Trevor Ziman's background is rooted in management and corporate leadership, giving him a strong foundation to navigate the complex and dynamic pharmaceutical landscape. Under his guidance, Aspen Pharmacare aims to strengthen its market position and deliver sustainable healthcare solutions across the Asia Pacific region.
With his deep insights into the Asia Pacific market, Mr. Ziman has contributed to the company's strategic growth and operational excellence in the region. His role involves overseeing operations, driving commercial strategies, and ensuring compliance with regional regulations. His leadership is crucial as Aspen continues to expand its footprint and enhance its product offerings in the Asia Pacific region.
Trevor Ziman's background is rooted in management and corporate leadership, giving him a strong foundation to navigate the complex and dynamic pharmaceutical landscape. Under his guidance, Aspen Pharmacare aims to strengthen its market position and deliver sustainable healthcare solutions across the Asia Pacific region.
Samer Kassem is a renowned executive within the pharmaceutical industry, known for his leadership role at Aspen Pharmacare Holdings Ltd., a global player in the pharmaceutical manufacturing and marketing sector. Serving as the Regional CEO for the Middle East and North Africa (MENA) at Aspen, Kassem has been instrumental in driving the company's strategic growth and operations across the region. With a strong background in both business development and management, Samer has accumulated extensive experience in the pharmaceutical field. Under his stewardship, Aspen's MENA operations have expanded significantly, reflecting his commitment to excellence and innovation. Prior to joining Aspen, Kassem held various senior positions in prominent pharmaceutical companies, where he honed his skills in leadership, strategy, and market expansion. His efforts have contributed substantially to Aspen's mission of providing high-quality, affordable medicines to those in need, aligning with the organization's broader goals of enhancing healthcare accessibility globally. Beyond his professional achievements, Samer Kassem is recognized for his ability to navigate complex markets and adapt to the dynamic needs of the pharmaceutical industry.
With a strong background in both business development and management, Samer has accumulated extensive experience in the pharmaceutical field. Under his stewardship, Aspen's MENA operations have expanded significantly, reflecting his commitment to excellence and innovation. Prior to joining Aspen, Kassem held various senior positions in prominent pharmaceutical companies, where he honed his skills in leadership, strategy, and market expansion.
His efforts have contributed substantially to Aspen's mission of providing high-quality, affordable medicines to those in need, aligning with the organization's broader goals of enhancing healthcare accessibility globally. Beyond his professional achievements, Samer Kassem is recognized for his ability to navigate complex markets and adapt to the dynamic needs of the pharmaceutical industry.
Luresha Chetty is a notable executive at Aspen Pharmacare Holdings Ltd, where she has held the position of Group Chief Financial Officer since April 1, 2023. Her extensive experience within the pharmaceutical industry marks her as a significant contributor to Aspen's financial strategies and operations. Before ascending to the role of CFO, Chetty dedicated 13 years to Aspen, proving her capabilities and leadership as Group Finance Executive. Her tenure at Aspen is characterized by her decisive role in the company’s financial management and strategic growth initiatives, underpinning her reputation as a capable and influential leader in the pharmaceutical sector.
